Gallium-DOTA-(Tyr3)-octreotide(68Ga) injection. Monograph N°: 2482 of the European Pharmacopoeia.This monograph is submitted to National Authorities for comment and will be simultaneously published in the next issue of Pharmeuropa (21.1). Virgolini I et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10.
International ethical guidelines for biomedical research involving human subjects. Council for International Organizations of Medical Sciences (CIOMS) World Health Organization (WHO). Geneva: CIOMS; 2002.
Guidance PET Drugs — Current Good Manufacturing Practice (CGMP) (Small Entity Compliance Guide). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) August 2011 Compliance
Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities. ENTR/F2/BL D(2003) Revision 2 (October 2005).
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use.
EANM Radiopharmacy Committee (March 2007) guidelines on current good radiopharmacy practice (CGRPP) in the preparation of radiopharmaceuticals.
EMEA Committee for Medicinal Products for Human Use. Guideline on the limits of genotoxic impurities. EMEA/CHMP/QWP/251344/2006. (June 2006).
EudraLex. The Rules Governing Medicinal Products in the European Union. Volume 4: EU Guidelines to Good Manufacturing Practice. Medicinal Products for Human and Veterinary Use. Part II: Basic Requirements for Active Substances used as Starting Materials. (October 2005).
European Commission, Radiation Protection 99: Guidance on Medical Exposures in Medical and Biomedical Research, Directorate General Environment, Nuclear Safety and Civil Protection; 1998.
Guideline on excipients in the dossier for application for marketing authorization of a medicinal product. EMEA/CHMP/ QWP/396951/2006 (November 2006).